Biocon shifts focus to margins, capacity utilisation after expansion phase

Biocon is shifting its strategy to focus on capacity utilization, margin expansion, and improved returns after significant investments in global capabilities. The company reported a 13% revenue increase for FY26, though net profit saw a substantial decline. Biocon is also prioritizing sustainable, profitable growth and exploring in-licensing opportunities for its biosimilars portfolio.